Comprehensive Summary: Refractory Ascites & Hyponatremia in Advanced Cirrhosis
Lecturer: Prof. Sanjaya Satapathy, MD, FAASLD
1. Main Clinical Topics Discussed
- Pathophysiology, definition, and classification of refractory ascites in advanced cirrhosis
- Dilutional hyponatremia in cirrhosis: mechanisms, prognostic significance, and management
- Transplant referral thresholds and timing
- Common clinical and board examination pitfalls
2. Key Learning Points, Guidelines, and Recommendations
Pathophysiologic Framework
- Advanced cirrhosis causes progressive splanchnic vasodilation → decreased systemic vascular resistance → falling mean arterial pressure → reduced effective arterial blood volume
- Ascites reflects circulatory dysfunction, not traditional volume overload
- These patients are hemodynamically fragile, highly preload-dependent, and vulnerable to small physiologic insults (hypoalbuminemia, NSAIDs, infections, overly aggressive diuresis, non-selective beta-blockers)
Definition and Classification of Refractory Ascites
- Refractory ascites: Ascites that cannot be adequately mobilized or recurs early despite strict sodium restriction and maximal tolerated diuretic doses
- Two distinct subtypes:
- Diuretic-resistant ascites: No meaningful response despite optimal dosing and dietary adherence
- Diuretic-intolerant ascites: Some response observed, but effective dosing is prevented by complications (AKI, significant hyponatremia, hypotension, or encephalopathy)
- Both subtypes carry equally poor prognosis and mandate escalation of care
Management of Refractory Ascites
- Optimize foundational measures first:
- Strict dietary sodium restriction
- Careful diuretic titration balancing efficacy vs. safety
- Discontinue nephrotoxic agents, particularly NSAIDs
- Rule out and treat spontaneous bacterial peritonitis (SBP) and other infections as reversible precipitants
- Large-volume paracentesis (LVP): First-line therapy for refractory ascites
- Safe and highly effective for rapid symptom relief
- Albumin replacement mandatory when >5 liters removed: 6–8 g albumin per liter of ascites removed
- Prevents post-paracentesis circulatory dysfunction, renal impairment, and hyponatremia
- Transjugular intrahepatic portosystemic shunt (TIPS):
- Appropriate for selected patients with burdensome symptoms refractory to repeated LVP and preserved liver function
- Contraindications: Severe or recurrent hepatic encephalopathy, heart failure, severe pulmonary hypertension, hepatopulmonary syndrome
- Role: Targeted intervention, often as a bridge to transplantation — not a default therapy
Hyponatremia in Cirrhosis
- Definition threshold: Serum sodium <130 mEq/L
- Mechanism: Non-osmotic ADH release driven by reduced effective arterial volume → disproportionate free water retention → dilutional hyponatremia (not sodium loss)
- Management principles:
- Fluid restriction useful only in selected patients with significant hyponatremia — not reflexively applied
- Identify and treat precipitating factors (infection, GI bleeding, medications)
- Discontinue diuretics when AKI, severe hyponatremia, or hypotension is present
- Do not treat the number alone — management guided by clinical status and trajectory
Hypertonic Saline
- Almost never indicated in cirrhotic hyponatremia
- Worsens volume overload and ascites without correcting underlying pathophysiology
- Narrow exception: Life-threatening neurologic symptoms (seizures, severe cerebral edema) — goal is short-term neurologic stabilization only, not sodium normalization
Vaptans (e.g., Tolvaptan)
- Transiently improve serum sodium but do not correct underlying pathophysiology
- No mortality benefit demonstrated; no improvement in complications or transplant outcomes
- Carry **real